The Fangzhou AI platform for pharmaceutical procurement and inventory management has been included in a 2026 collection of best practices for drug distribution, the company said on October 27.

Key Takeaways

  • The recognition was announced at a pharmaceutical distribution conference in Guangzhou.
  • Fangzhou also uses AI applications in its chronic disease services.

Fangzhou AI platform gains industry recognition

The platform, formally named the AI Algorithm-Based Pharmaceutical Procurement and Inventory Coordination Platform, was included in the 2026 Collection of Best Practices for High-Quality Pharmaceutical Distribution Development.

The recognition was announced at the 10th Pharmaceutical Distribution Review and Certification Technology Conference, organized by the Guangdong Food and Technology Association for Evaluation and Certification. The conference’s showcase was established to identify and promote digital innovations in the industry.

AI applications extend to chronic disease care

Fangzhou said it has integrated AI into patient services, physician support and operations as part of its chronic disease services strategy. Its applications use the company’s XingShi large language model.

The company said its AI Health Manager and AI Medication Assistant support patients, while pre-consultation tools and an AI Academic Assistant are designed to help physicians. As of June 30, 2026, Fangzhou reported 59.8 million registered users and 282,000 physicians.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.